CHI’s Protein Kinase Targets

Venue: Boston,

Location: Boston,, Massachusetts, United States

Event Date/Time: Jun 06, 2005 End Date/Time: Jun 07, 2005
Report as Spam


Many models for designing selective protein kinase inhibitors are based on "standardized" data. Is this satisfactory for pharma? What can be done to make those models better? Do we need new data models? Is it better to create whole models or is a model of the active site sufficient? What data is needed for localized mapping? What impact does the fingerprinting of ligand interactions have? How can we increase the efficiency of existing targets? How can industry and academia improve their collaboration in order to reach the full potential which protein kinases present as druggable targets? Which data are still missing?

Protein kinases, as one of the major druggable groups, present an exciting opportunity for therapeutic development. Currently a great deal of effort is being put into finding and improving new ways to modify their activity. Join the 3rd Annual Protein Kinase Targets conference, which will bring together scientists from industry and academia to present current strategies of how to modify the protein kinase activity and address current bottleneck issues in panel discussions. Furthermore, roundtable discussions will focus on brain-storming what can be done in the future to enhance the successful development of protein kinase inhibitors as therapeutics.